At a glance
- Company
- Quantum BioPharma Ltd.
- Ticker
- NASDAQ: QNTM, CSE: QNTM
- Announcement
- Regulatory
Key figures
- Phase 1 studies
- Phase 1
- Planned clinical trial
- Phase 2
- IND application submission
- April 2026
- Quantum BioPharma ownership of UWI
- 19.84%
- Royalty rate on unbuzzd sales until threshold
- 7%
- Royalty threshold
- $250 million
Products and programs
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured in a recent article that discussed its advancement of its proprietary multiple sclerosis therapy candidate, LUCID-MS, which is designed to target demyelination and protection or restoration of myelin integrity. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The company believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation, while also strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
To view the full article, visit https://ibn.fm/AUhNl
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of March 31, 2026) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
Quantum BioPharma says its LUCID-MS multiple sclerosis candidate is advancing toward patient-focused clinical studies. The company reports that Phase 1 studies in healthy volunteers found a favorable safety profile and that the candidate was generally well tolerated. In April 2026, it submitted an Investigational New Drug application to the U.S. Food and Drug Administration, enabling a planned Phase 2 trial involving people with multiple sclerosis. The company describes LUCID-MS as targeting myelin loss and neurodegeneration and says it is strengthening program support through a planned partnership with Allucent and engagement with neurological specialists. LUCID-MS is being developed through the company’s wholly owned subsidiary, Lucid Psycheceuticals. The release also notes Quantum BioPharma’s stake and royalty arrangement relating to unbuzzd, an OTC product it spun out to Unbuzzd Wellness.
Key takeaways
- Quantum BioPharma says Phase 1 studies in healthy volunteers found LUCID-MS generally well tolerated, with a favorable safety profile.
- The company submitted an IND application for LUCID-MS to the FDA in April 2026.
- A Phase 2 trial in people with multiple sclerosis is planned.
- The company says it plans to support the program through a partnership with Allucent and engagement with neurological specialists.
